SCHEMBL25109166

SCHEMBL25109166

CC(S)C(=O)NCCOCCN1CCN(C(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TP53 P04637 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ USP2 O75604 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.36
▸ CYP2C19 P33261 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ HTR4 Q13639 1/20 0.35
▸ PTGS2 P35354 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ DAO P14920 1/20 0.35
▸ DRD2 P14416 1/20 0.34
▸ DRD4 P21917 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ FPR3 P25089 1/20 0.34
▸ FPR2 P25090 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21107906 0.99 MEN1 (0.45) MEN1KMT2ATP53SMN1; SMN2USP2
SCHEMBL21107025 0.89 MEN1 (0.45) MEN1KMT2ATP53SMN1; SMN2USP2
SCHEMBL22856287 0.88 MEN1 (0.47) MEN1KMT2ATP53SMN1; SMN2USP2
SCHEMBL21107592 0.88 MEN1 (0.47) MEN1KMT2ATP53SMN1; SMN2USP2
SCHEMBL25972108 0.86 TP53 (0.40) MEN1KMT2ATP53SMN1; SMN2SIGMAR1
SCHEMBL23945709 0.85 TP53 (0.41) MEN1KMT2ATP53SMN1; SMN2SIGMAR1
SCHEMBL24765441 0.83 MEN1 (0.41) MEN1KMT2ATP53SMN1; SMN2SIGMAR1
SCHEMBL21106866 0.83 MEN1 (0.41) MEN1KMT2ATP53SMN1; SMN2SIGMAR1
SCHEMBL25477805 0.81 SMN1; SMN2 (0.44) MEN1KMT2ATP53SMN1; SMN2USP2
SCHEMBL23696085 0.81 DRD4 (0.43) MEN1KMT2ATP53SMN1; SMN2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-11679109-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-06-20 — — US disclosed
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 MEN1 2085/4885KMT2A 73/4885TP53 350/4885
US-11679109-B2 SMARCA degraders and uses thereof SMARCA1, SMARCA2, SMARCC2 MEN1 2085/4885KMT2A 73/4885TP53 350/4885
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 MEN1 1348/4885KMT2A 380/4885TP53 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback